Potent Human Single-Domain Antibodies Specific for a Novel Prefusion Epitope of Respiratory Syncytial Virus F Glycoprotein-Reference-Cited by-同舟云学术

Potent Human Single-Domain Antibodies Specific for a Novel Prefusion Epitope of Respiratory Syncytial Virus F Glycoprotein

Published:2021-08-25 Issue:18 Volume:95 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Xun Guangjin¹²,Song Xingpan³,Hu Jie³,Zhang Haiwei¹,Liu Lan¹,Zhang Zhe¹,Gong Rui¹²^ORCID

Affiliation:

1. CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China

2. University of Chinese Academy of Sciences, Beijing, China

3. Wuhan Banke-Biotechnology LLC, Wuhan, Hubei, China

Abstract

Because respiratory syncytial virus (RSV) can cause serious respiratory disease in immunodeficient groups, including infants and seniors, the development of vaccines and therapeutic drugs, such as neutralizing antibodies, is urgently needed. Compared to the conventional full-length antibody, a single-domain antibody (sdAb) has been demonstrated to be efficient for respiratory diseases when administered by inhalation, thereby potentially introducing a kind of novel therapeutic agent in the market.

Funder

"One-Three-Five" Strategic Programs of Wuhan Institute of Virology, Chinese Academy of Sciences

Natural Science Foundation of Hubei Province

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/JVI.00485-21

Reference60 articles.

1. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study

2. Risk of Primary Infection and Reinfection With Respiratory Syncytial Virus